A Post-Market Clinical Evaluation of the Treatment of Femur Fractures with the Femoral Nail Greater Trochanter (GT) of the T2 Alpha Femur Antegrade GT/PF Nailing System

Go Back to All Clinical Trials

A Post-Market Clinical Evaluation of the Treatment of Femur Fractures with the Femoral Nail Greater Trochanter (GT) of the T2 Alpha Femur Antegrade GT/PF Nailing System

Brief description of study

This prospective, multi-center, clinical investigation, designed to examine the safety and efficacy/performance of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System. Over the past decades femoral nailing has become the treatment of choice for most femoral fractures. As an addition to the femoral nails, Stryker has created a new generation femoral implant, the T2 Alpha Femur Antegrade Greater Trochanter (GT) Nail. This device is not an experimental medical device and is approved by the United States Food and Drug Administration (FDA).

Clinical Study Identifier: s18-00733

ClinicalTrials.gov Identifier: NCT04015128

Principal Investigator: Nirmal C Tejwani.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies